Developing pet medications that have superior convenience and therapeutic benefits, thereby delivering improved healthcare to pets and economic returns to our investors and strategic partners.
Velcera Home
About Velcera
Velcera Technology
Clinical Pipeline
Business Development
Velcera Investor Relations
Contact Velcera
June 30, 2008
Velcera Announces FDA Confirms VEL504 Clinical Program
June 19, 2008
Velcera Appoints Sal Uglietta to Board of Directors
June 9, 2008
Velcera Announces Completion of Enrollment in VEL502 Clinical Trial
June 2, 2008
Velcera Announces Positive FDA Meeting on VEL504 Product
April 24, 2008
Velcera Announces Initiation of Clinical Trial with VEL502

Velcera's mission is to bring innovation to the expanding pet health market by providing products that have superior convenience and greater compliance that can improve pet health and provide attractive economic returns to our investors and strategic partners.

The company is ideally positioned to fulfill this mission based upon Velcera's patented Promist™ delivery system, with its ease of treating pets and its pharmacokinetic advantages, combined with its pet health industry expertise. Established in 2004, Velcera has attracted some of the top leaders in pet health to develop and deploy the innovative Promist delivery technology.